Security Snapshot

Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) Institutional Ownership

CUSIP: 45719W205

13F Institutional Holders and Ownership History from Q1 2023 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

75

Shares (Excl. Options)

108.16MFull value: 108,162,860 · shares · 30 Sep 2026

Price

$2.06

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+9,853,651
Value change
+$20,251,625
Number of holders
75
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
135,127,605
SEC-reported price per share
$1.67
Insider filing price
$1.67
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 45719W205.
  • 75 institutions reported positions in Q3 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 105 to 75 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $239.2MFull value: $239,197,795 · USD · 30 Jun 2026
    to
    $222.34MFull value: $222,341,130 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 75 institutions filings for Q3 2026.

Open SEC evidence

Security key

45719W205

13F reference period

Q3 2026

13F holders

75

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
IKT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% -38% $29,894,148 -$21,105,852 14,653,994 -41% RA Capital Management, L.P. 29 Jul 2026
Commodore Capital LP 9.9% $25,439,441 14,054,940 Commodore Capital LP 31 Mar 2026
ADAR1 Capital Management, LLC 9.9% 0% $25,086,651 +$2,113,430 13,860,028 +9.2% ADAR1 Capital Management, LLC 31 Mar 2026
Sands Capital Life Sciences Pulse Fund II, L.P. 9.3% -14% $26,558,689 13,018,965 0% Sands Capital Life Sciences Pulse Fund II, L.P. 30 Jun 2026
Fairmount Funds Management LLC 9.9% 0% $24,922,202 +$10,885,052 12,461,101 +78% Fairmount Funds Management LLC 31 Dec 2025
PERCEPTIVE ADVISORS LLC 6.9% -22% $21,054,585 -$4,722,600 10,320,875 -18% Perceptive Advisors LLC 30 Jun 2026
Trails Edge Capital Partners, LP 6.1% +20% $14,583,794 +$3,460,986 8,057,345 +31% Trails Edge Capital Partners, LP 31 Mar 2026
BlackRock, Inc. 5.9% $15,770,602 7,768,004 BlackRock, Inc. 30 Jun 2026
Nantahala Capital Management, LLC 4.3% -23% $11,853,393 -$2,503,955 5,810,487 -17% Nantahala Capital Management, LLC 30 Jun 2026
ARMISTICE CAPITAL, LLC 5% $7,975,554 3,529,006 Armistice Capital, LLC 31 Dec 2024
As of 30 Sep 2026, 75 institutional investors reported holding
108.16MFull value: 108,162,860 · shares · 30 Sep 2026
shares of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT). This represents 80% of the company’s total
135.13MFull value: 135,127,605 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
75%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Sands Capital Alternatives, LLC 9.6% 13,018,965 3.9% $26,819,068
Soleus Capital Management, L.P. 8.3% 11,225,000 0.82% $23,067,375
Trails Edge Capital Partners, LP 6.7% 9,110,112 2.7% $18,721,280
Fairmount Funds Management LLC 6.4% 8,625,000 1.1% $17,724,375
RA CAPITAL MANAGEMENT, L.P. 5.2% 6,970,000 0.14% $14,323,350
Siren, L.L.C. 4.3% 5,850,000 0.28% $12,021,750
Blackstone Inc. 4.3% 5,796,806 0.04% $11,912,436
Commodore Capital LP 4% 5,397,488 0.86% $11,091,838
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 5,053,455 0% $10,384,850
Saturn V Capital Management LP 2.9% 3,869,056 1.2% $7,950,910
Kalehua Capital Management LLC 2.8% 3,821,890 5.9% $7,853,984
Spruce Street Capital LP 2.7% 3,581,603 1.2% $7,360,194
GEODE CAPITAL MANAGEMENT, LLC 2.3% 3,063,159 0% $6,295,955
STATE STREET CORP 1.6% 2,222,640 0% $4,567,525
Squadron Capital Management LLC 1.5% 2,000,000 1.2% $4,110,000
Nantahala Capital Management, LLC 1.4% 1,951,863 0.23% $4,011,078
SummitTX Capital, L.P. 1.3% 1,781,010 0.1% $3,659,976
Tyro Capital Management LLC 1% 1,368,756 0.5% $2,812,793
Integral Health Asset Management, LLC 1% 1,350,000 0.17% $2,774,250
TWO SIGMA INVESTMENTS, LP 0.75% 1,008,503 0% $2,072,474
VANGUARD PORTFOLIO MANAGEMENT LLC 0.73% 984,371 0% $2,022,882
Kennondale Capital Management LLC 0.53% 721,961 0.96% $1,483,630
SPHERA FUNDS MANAGEMENT LTD. 0.51% 688,301 0.21% $1,414,459
VANGUARD FIDUCIARY TRUST CO 0.5% 681,099 0% $1,399,658
Stonepine Capital Management, LLC 0.48% 647,285 1.1% $1,330,171

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
15
Headline period
Q3 2026
Rows shown
1-15 of 15
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 108,162,860 $222,341,130 +$20,251,625 $2.06 75
2026 Q2 117,856,617 $239,197,795 +$6,932,800 $2.03 105
2026 Q1 115,144,233 $193,410,814 +$11,923,696 $1.68 104
2025 Q4 106,415,262 $218,151,569 +$72,128,708 $2.05 73
2025 Q3 54,964,771 $89,043,214 +$712,913 $1.62 53
2025 Q2 54,512,097 $106,299,597 +$5,482,917 $1.95 48
2025 Q1 51,462,756 $112,702,942 +$3,027,389 $2.19 47
2024 Q4 50,059,308 $162,691,896 +$161,164,562 $3.25 31
2024 Q3 860,232 $1,118,330 +$30,199 $1.30 11
2024 Q2 836,496 $1,021,038 +$723,392 $1.21 12
2024 Q1 205,558 $443,782 -$62,190 $2.16 12
2023 Q4 235,004 $298,925 -$271,105 $1.27 11
2023 Q3 429,662 $597,627 -$496,803 $1.39 13
2023 Q2 747,138 $2,693,647 +$2,394,678 $3.61 14
2023 Q1 82,817 $54,460 +$54,460 $0.66 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .